Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum

Study:

Evaluation of Aminocamptothecin (9-AC, NSC #603071) in Recurrent, Platinum Resistant and Refractory Ovarian Cancer and Primary Peritoneal Carcinoma

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Purpose:

Phase II trial to study the effectiveness of aminocamptothecin in treating patients with recurrent or refractory ovarian epithelial cancer or primary cancer of the peritoneum.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Drug: aminocamptothecin colloidal dispersion Phase 2

Verified by Gynecologic Oncology Group June, 2005

Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00003523

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States

David S. Miller, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site